About
Kevin is the interim president of Editas Medicine and a principal at Polaris Partners. He joined Polaris in 2004 and focuses on investments in health care. Kevin is a co-founder of Genocea Biosciences and Sirtris Pharmaceuticals (acquired by GSK) and was the founding CEO at Visterra Inc. (formerly Parasol Therapeutics). He currently represents Polaris as a director of InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical and Vets First Choice. Additionally, he is a board observer to Arsenal Medical and 480 Biomedical.Kevin holds a Ph.D. in genetics from Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.
Position in the VCSift Database
- • 19 investors at Atlas Venture are tracked.
- • 2,531 investors hold the Partner role in VCSift. Kevin Bitterman is one of them.
- • 2,293 investors are based in Boston, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- Boston, US
Contact Information
Find more investors like Kevin
Search Investors